Beyersdorf F
Department of Cardiovascular Surgery, Albert-Ludwigs University, Freiburg, Germany.
Ann Thorac Surg. 2001 Mar;71(3 Suppl):S192-4; discussion S202-3. doi: 10.1016/s0003-4975(00)02617-5.
Among the treatment options for congestive heart failure, ventricular assist devices (VADs) are an emerging new technology, which may serve as a realistic therapeutic option once the complication rate is reduced. Whereas these devices were used in the past almost exclusively as a bridge to transplant, today permanent VAD and full-implantable VAD are considered for destination therapy. It is therefore necessary to compare this treatment modality with other current strategies with regard to not only current survival, quality of life, and complication metrics but also relative costs between treatments. Comparable studies evaluating treatment costs are rare and future research must focus on theses issues because of the demands of permanent cost containment.
在充血性心力衰竭的治疗选择中，心室辅助装置（VADs）是一项新兴的新技术，一旦并发症发生率降低，它可能成为一种切实可行的治疗选择。过去，这些装置几乎仅用作移植的桥梁，而如今，永久性VAD和完全植入式VAD被考虑用于终末期治疗。因此，有必要将这种治疗方式与其他当前策略进行比较，不仅要比较当前的生存率、生活质量和并发症指标，还要比较治疗之间的相对成本。由于长期成本控制的要求，评估治疗成本的可比研究很少，未来的研究必须关注这些问题。
